Peptide education
Vasopressin
Arginine vasopressin · AVP · Antidiuretic hormone · ADH · Vasostrict
Vasopressin is a nine-amino-acid hormone, known in medicine as antidiuretic hormone and in the ICU as an intravenous pressor for vasodilatory shock. It tightens blood vessels, tells the kidney to hold water, and, in the brain, modulates social attention and threat processing. The online version is a nasal spray for social ease, memory, and autism, built from small experiments and one small pediatric trial. Those are three different conversations wearing one name.
The approval is real but it belongs to the ICU: monitored IV infusion for shock. The brain claims rest on one 30-child autism pilot, acute lab-task effects, and decades-old sleep studies, and the pathway's biggest controlled test, the V1a antagonist balovaptan, failed.
Overview
Quick answer
Hospital IV vasopressin, experimental intranasal vasopressin, desmopressin nasal products, oxytocin-style social claims, and research-use online vials put the same hormone family into very different settings. Route, product controls, monitoring, and source behind the claim all change whether evidence from one setting can be applied to another product, route, or claim.
What is vasopressin?
An endogenous nonapeptide acting at V1, V2, and V3 receptors: vascular tone, water retention, pituitary signaling, and central social-behavior circuits. The approved drug is IV vasopressin for adults in vasodilatory shock, not a nasal consumer product.
Why do people talk about it for the brain?
Central vasopressin signaling touches social attention, face processing, cooperation, and threat circuitry, and CSF biomarker work ties it to autism biology. That justified the studies; it did not deliver a treatment, and the acute effects point in different directions depending on task and person.
What dose and route details appear in the record?
The label titrates IV infusion from 0.01 U/min in septic shock and 0.03 U/min after cardiotomy under ICU monitoring. Intranasal research used single 20 or 40 IU doses in adults, 24 to 32 IU/day for four weeks in the pediatric autism pilot, and a planned 16 IU twice daily for eight weeks in the follow-up study.
What does the internet market add?
Research-reagent listings, legacy nootropic pages with broad memory language, and scattered forum experiments. Consistent dosing, verified product, and follow-up are missing from all of it.
What is the main safety issue?
Vasopressin constricts coronary, mesenteric, skin, and digital vessels and can pull serum sodium down; the IV label carries ischemia and hyponatremia warnings, and the autism study monitored specifically for water intoxication. A gray-market vial adds identity, sterility, and concentration risk on top of pharmacology that was never casual.
Reported practice
Commonly reported protocol
Hospital and sparse community context. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
FDA and DailyMed labeling describe IV vasopressin for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Large septic-shock trials help place vasopressin in critical-care practice, but they do not create a consumer peptide claim for mortality, kidney outcomes, or wellness use.
A four-week randomized pediatric autism pilot reported improved social scores with intranasal vasopressin. A phase II registry record documents a planned intranasal regimen, but no posted positive efficacy result is cited here; it is study-design context, not confirmation.
Acute intranasal studies in healthy volunteers reported changes in face encoding, cue recognition, social attention, cooperation, and brain activation. The effects vary by task, sex, and setting.
FDA compounding materials, research-use listings, and peptide quality papers point to quality concerns around online vasopressin products and COA-heavy marketing.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Vasopressin is FDA-approved for autism, cognition, or social enhancement. | No; U.S. approval is for IV vasopressin in adult vasodilatory shock. The autism and social-cognition material is investigational intranasal research. | Central vasopressin signaling is relevant to social behavior, but a relevant pathway does not create an approved neuropsychiatric indication. | Online nootropic and anti-aging discussion sometimes treats vasopressin as a brain peptide. That shows the public narrative, not approval evidence. | Not accurate as stated. Approval is for the monitored IV shock product, while brain and social claims remain experimental. |
| Vasopressin may help social functioning in autism. | A small randomized pilot in 30 children with autism reported improvement on SRS-2 social scores over four weeks. A larger study used 16 IU twice daily for eight weeks, but no posted positive efficacy result was found. | CSF vasopressin biomarker work in primates and children supports interest in the pathway, and later CSF-versus-blood work suggests brain-relevant biology may not be captured well by blood measures. | Autism and social-use discussion appears online, but the research case is narrower: one small trial signal plus biomarker rationale, not forum reports by themselves. | Early and research-relevant. Too small and incomplete for a clinical treatment claim. |
| Vasopressin is a broad memory or nootropic peptide. | The human evidence is narrower. One acute study in healthy men reported better encoding of happy and angry faces, and an older three-month elderly study reported specific recall and interference findings rather than a broad memory upgrade. | Vasopressin can change attention to social stimuli and neural processing, but those task effects do not equal generalized cognition enhancement. | Older nootropic and anti-aging pages use broader memory language than the human study pattern can carry. | The studies point to task-specific research interest, not a dependable nootropic claim. |
| Vasopressin improves sleep. | Small older randomized studies in healthy elderly adults reported improved slow-wave sleep and objective sleep architecture using intranasal schedules over 10 weeks to three months. | Vasopressin interacts with pituitary-adrenal and central signaling that can plausibly affect sleep physiology. | Sleep claims appear in broader online wellness discussion, but the human studies are older and small. | A narrow elderly sleep research signal, not a modern sleep-treatment or wellness claim. |
| Intranasal vasopressin reliably reaches the brain. | One human ERP comparison reported central effects after intranasal vasopressin under conditions where matched IV dosing did not. Other delivery work is mixed and does not guarantee reliable exposure for every nasal product. | Nose-to-brain delivery is possible, but it depends on formulation, device, anatomy, dose, and product quality. | Gray-market nasal-spray discussion often assumes that nasal use equals brain delivery. The delivery literature is more mixed. | Possible under some study conditions, but not guaranteed for online or compounded products. |
| What can a vendor COA tell you about a vasopressin product? | This is a manufacturing and product-control question, not an efficacy trial question. FDA compounding materials and peptide quality papers show why a posted COA is just one narrow document. | Identity, purity, peptide-related impurities, concentration, sterility, endotoxin, stability, storage, fill accuracy, and lawful manufacturing all affect risk. | Research reagent pages sell vasopressin as laboratory material and older online pages discuss goals people associate with human use. Those signals are not a finished-drug quality system. | A COA can help characterize a sample, while pharmaceutical quality depends on the finished-drug system around that sample. |
Bottom line
Main takeaway
Vasopressin is a hospital pressor and water-balance hormone; the nasal brain version discussed online is early research, not an established use.
The human brain evidence is one small positive pediatric pilot, a set of single-dose lab-task studies pointing in mixed directions, old elderly sleep trials, and a larger autism study record with no posted efficacy result. Do not let the FDA-approved IV drug lend credibility to any of it.
Anchor on the Vasostrict label and the VASST and VANISH trials for the real drug, Parker 2019 plus the NCT03204786 record for the autism question, the acute intranasal task literature for mechanism, and the balovaptan failures as the pathway's warning label.
Identity
What it is
Vasopressin is the posterior pituitary's other nonapeptide, structurally close to oxytocin and almost opposite in reputation. Through V1 receptors it constricts blood vessels; through V2 receptors it makes the kidney reclaim water; through central V1a pathways it tunes how animals, and apparently people, attend to social cues.
Its medical identity is unambiguous. The FDA label covers one thing: IV infusion to raise blood pressure in adults with vasodilatory shock who stay hypotensive despite fluids and catecholamines. Large septic-shock trials then mapped where it helps and where it does not, without showing broad superiority over norepinephrine.
Its research identity is genuinely interesting and genuinely small. A four-week intranasal pilot in 30 children with autism improved social-responsiveness scores. Single-dose lab studies shifted face encoding, cooperation, and attention, sometimes differently by sex. Older small trials in elderly volunteers reported better slow-wave sleep and selected memory effects. The larger autism follow-up has a registry record and a monitoring plan, not a posted positive result.
Its market identity is a warning. Research-use vials and nootropic pages borrow the ICU drug's legitimacy for a molecule that can cause ischemia and hyponatremia, and FDA excluded vasopressin from the 503B compounding bulks list for lack of demonstrated clinical need.
How people talk about it online
Online vasopressin talk splits between reagent listings and lore. Sellers move research-use vials under laboratory disclaimers, while older nootropic and anti-aging pages repeat memory and cognition language the human studies, small and task-bound as they are, never supported.
Forum reports are thin even by peptide-market standards: no converged protocol, no consistent dose, a handful of nasal-spray self-experiments. The signal in that noise is demand, not effect.
The persistent error is borrowed authority. An approved ICU infusion, an experimental trial spray, and a mail-order vial share a molecule name and almost nothing else: not oversight, not dosing, not evidence.
Use context
Routes, doses, and cycle patterns
Vasopressin use patterns split by setting. The label describes IV infusion in critical-care shock. Human neuro studies used intranasal doses under research conditions. Online and gray-market discussion tends to talk about nasal sprays or research vials, but consistent dosing and cycle details are not reliable there.
Human studies and product labels
Septic shock label pattern
- Purpose
- Blood-pressure support in adults with vasodilatory shock
- Context
- FDA label
- Route
- Intravenous infusion
- Amount
- Start 0.01 U/min; limited data above 0.07 U/min
- Frequency
- Continuous infusion with titration by 0.005 U/min every 10 to 15 minutes
- Duration
- Critical-care duration; exact duration depends on clinical course
This is a monitored inpatient pressor schedule, not an outpatient peptide or outpatient-use pattern.
Post-cardiotomy shock label pattern
- Purpose
- Blood-pressure support after cardiotomy shock
- Context
- FDA label
- Route
- Intravenous infusion
- Amount
- Start 0.03 U/min; limited data above 0.1 U/min
- Frequency
- Continuous infusion with titration by 0.005 U/min every 10 to 15 minutes
- Duration
- Critical-care duration; exact duration depends on clinical course
The labeled route and monitoring context are the important facts. It does not justify nasal, wellness, cognition, or online-product claims.
Pediatric autism pilot
- Purpose
- Autism-related social impairment research
- Context
- Randomized placebo-controlled pilot
- Route
- Intranasal
- Amount
- 24 IU/day target for ages 6 to 9.5; 32 IU/day target for ages 9.6 to 12.9
- Frequency
- Daily dosing in the four-week study
- Duration
- Four weeks
The trial reported improved social scores and tolerability in a small, selected pediatric sample. It requires larger confirmation before it can be read as clinical practice.
Autism phase II study design
- Purpose
- Planned confirmatory autism research
- Context
- ClinicalTrials.gov study record
- Route
- Intranasal
- Amount
- 16 IU twice daily
- Frequency
- Twice daily
- Duration
- Eight weeks
The record describes a planned regimen and monitoring plan, not an efficacy result.
Acute social-cognition studies
- Purpose
- Face encoding, cue recognition, emotion processing, and social tasks
- Context
- Randomized laboratory studies
- Route
- Intranasal
- Amount
- Single 20 IU or 40 IU doses in different studies
- Frequency
- Single-dose experimental sessions
- Duration
- Acute task windows, often with a 45-minute wait before testing
These studies show task and circuit effects in controlled settings. They do not answer repeated-use benefit questions.
Elderly memory and sleep studies
- Purpose
- Memory, slow-wave sleep, and sleep architecture research
- Context
- Older randomized studies
- Route
- Intranasal
- Amount
- 40 IU/day; or 20 IU before bed and 20 IU after awakening in sleep studies
- Frequency
- Daily schedules
- Duration
- Ten weeks to three months
These are small, older studies. They provide history, not a modern consumer sleep or nootropic program.
Real-world discussion
Hospital and sparse community context
- Purpose
- Cognitive discussion, separate from its critical-care role
- Context
- Research coverage and scattered biohacking reports
- Route
- Intranasal in cognitive discussion; IV infusion is the hospital form
- Amount
- No consistent community range exists
- Frequency
- Inconsistent
- Duration
- Inconsistent
Vasopressin is a critical-care drug with serious hemodynamic effects; the cognitive biohacking discussion around intranasal forms is thin and not a developed practice. Shared here as context, not instruction.
What varies
- Route: IV shock data and intranasal neuro studies cannot be merged into one claim.
- Product: approved injection, trial nasal product, compounded material, and research-use vials carry different controls.
- Goal: blood-pressure rescue, autism research, social attention, sleep, and nootropic use have different evidence.
- Monitoring: sodium, water balance, cardiac function, ischemia, and behavioral effects matter more than casual peptide-market language suggests.
Human data
Human evidence
Human evidence splits cleanly. For critical care the footing is strong: FDA labeling plus the VASST and VANISH septic-shock trials define vasopressin as a legitimate pressor option without broad outcome superiority. For the brain, everything is preliminary: one four-week pediatric autism pilot with improved social scores, acute single-dose studies with task- and sex-dependent effects, elderly sleep and memory studies from decades ago, and delivery literature that cannot promise any given nasal product reaches the brain. The larger autism study exists as a design, not a result. And balovaptan's failed V1a antagonist program is reason to hold the whole social-function story loosely.
Evidence maturity
Vasopressin is an approved ICU pressor, but its intranasal brain and social-function evidence is early, small, and still investigational.
A nine-amino-acid hormone acting at V1, V2, and V3 receptors across vascular tone, water balance, and central social signaling.
FDA-approved IV vasopressin raises blood pressure in adults with vasodilatory shock, with large septic-shock trials defining its ICU role.
Acute studies reported task-specific social-cognition effects, and one small pediatric autism pilot reported improved social scores over four weeks.
A larger autism study record documents a planned regimen without a posted positive efficacy result, and the related V1a-antagonist balovaptan failed larger trials.
Research-use vials and nootropic discussion exist, but no neuro indication is approved and FDA excluded vasopressin from the 503B compounding bulks list.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| FDA/DailyMed vasopressin injection labeling | Adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines | Prescribing information | Approved IV vasopressin injection | Defines the approved U.S. product context, route, indication, infusion ranges, warnings, adverse reactions, and overdose risks. | This label describes monitored IV pressor use, not autism, memory, sleep, social, anti-aging, or nasal consumer claims. | Strong |
| VASST and VANISH septic-shock trials | Adults with septic shock | Randomized critical-care trials | Hospital vasopressor use | Places vasopressin in the septic-shock pressor literature without showing simple superiority across major hard outcomes. | Shock trials describe ICU pressor decisions, not outpatient peptide-market or neuro claims. | Strong for ICU context |
| Parker 2019 intranasal vasopressin autism pilot | 30 children with autism spectrum disorder | Four-week randomized placebo-controlled pilot | Investigational intranasal research | Reported improved SRS-2 social scores, with additional anxiety and repetitive-behavior signals and tolerability in the selected sample. | Small, short, pediatric, and not paired here with a larger confirming efficacy result. | Preliminary |
| NCT03204786 autism phase II study record | Children ages 6 to 17 with autism spectrum disorder | Randomized/SPCD study design | Investigational intranasal study regimen | Documents a planned 16 IU twice-daily, eight-week regimen with safety monitoring for risks such as hyponatremia and water intoxication. | A study record is not an efficacy result. | Study record only |
| Acute intranasal social-cognition studies | Mostly healthy adult volunteers, often male-only | Randomized lab tasks, fMRI, ERP, and social-interaction paradigms | Investigational intranasal research | Reported changes in face encoding, sexual cue recognition, emotion circuitry, TPJ activity, cooperation, approachability, cue processing, and social attention. | Effects are task-specific, short-term, sex-dependent in some work, and not clinical outcomes. | Limited to moderate |
| Perras elderly memory and sleep studies | Healthy elderly adults | Older randomized placebo-controlled studies | Intranasal research | Reported selected memory/interference findings and improved slow-wave sleep or sleep architecture under repeated intranasal schedules. | Small, dated, narrow, and not a modern replicated sleep or nootropic program. | Limited |
| Intranasal delivery and biomarker literature | Human, primate, animal, and review sources | ERP comparison, delivery studies, review, and CSF biomarker work | Mechanism and delivery research | Shows why scientists care about central AVP signaling, CSF biomarkers, and possible nose-to-brain effects under some conditions. | Delivery and responder biology remain unsettled and product-dependent. | Moderate for mechanism, weak for consumer products |
| Balovaptan comparator trials | Adults and children with autism spectrum disorder | Vasopressin-pathway antagonist trials | Comparator pathway research, not vasopressin itself | Early interest in V1a antagonism was followed by larger negative adult and pediatric trial results. | Balovaptan is not vasopressin, but the failed pathway program warns against simplistic vasopressin-pathway claims. | Cautionary comparator |
Use context
Reported use context
Outside the labeled ICU and intranasal-research settings detailed under Use patterns, reported vasopressin use comes from research-reagent sellers and nootropic, anti-aging, or forum discussion of nasal or research-use products. None of it is an approved use.
Real-world discussion
Products are presented for laboratory use rather than labeled human treatment; availability does not verify identity, sterility, endotoxin control, or clinical suitability.
Memory, social, sleep, and anti-aging themes appear, but dosing, duration, product identity, and follow-up are inconsistent; this helps show claims people encounter, but it is not an efficacy record.
Cautions
Safety and unknowns
- IV vasopressin labeling warns about decreased cardiac output, arrhythmias, ischemia in coronary, mesenteric, skin, or digital beds, hyponatremia, reversible diabetes insipidus after discontinuation, and pregnancy-related uterine contraction concerns.
- Short-term intranasal studies looked tolerable in selected research groups, but they do not settle long-term cardiovascular, electrolyte, developmental, behavioral, or subgroup risk.
- The autism study design specifically monitored sodium and water-intoxication concerns, and it considered aggression because vasopressin can have context-dependent behavioral effects in animal work.
- Delivery remains uncertain. Nasal use may produce central effects under some conditions, but route, device, formulation, anatomy, and manufacturing quality can change exposure.
- The vasopressin pathway is not automatically therapeutic. Balovaptan, a V1a antagonist rather than vasopressin itself, had larger negative autism trial results after earlier interest.
Product quality
A vial label is only a starting point
Approved hospital vasopressin injection comes with a different control system than an online research vial, compounded nasal spray, or vendor-listed peptide. Product identity and sterile finished-product controls matter because vasopressin has real cardiovascular and water-balance biology.
FDA compounding materials say compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing. FDA also excluded vasopressin from the 503B bulks list after finding clinical need for bulk compounding was not found.
Identity
A label saying "vasopressin" does not verify the vial contains the right peptide, salt form, concentration, or finished formulation.
Sterility and endotoxin
Nasal and injectable products raise contamination questions that a simple purity percentage leaves open.
COA limits
Supplier COAs can help, but FDA quality guidance treats them as part of a qualified-supplier system, not as standalone evidence of finished-drug quality.
Research-use labeling
Research-use listings show market access and marketing context. They are not approved human-medicine labels.
Mechanism
How it is proposed to work
Vasopressin works through receptor systems that affect blood vessels, water balance, pituitary signaling, and brain circuits involved in social behavior. The same biology that makes it clinically potent also makes casual online claims risky.
In shock, vasopressin mainly supports vascular tone through V1 receptor signaling, while V2 signaling is tied to antidiuretic water handling.
Central vasopressin signaling can change how people process social cues, threat, cooperation, faces, attention, and affiliation. The findings do not point in one simple "more social" direction.
CSF vasopressin biomarker work supports a brain-relevant autism research hypothesis, but blood vasopressin may not track the same signal.
Intranasal delivery remains a formulation and exposure question. Some human and primate data support central effects, while other animal and review evidence keeps the mechanism unsettled.
Vasopressin is a nine-amino-acid hormone acting at V1 (vascular), V2 (renal), and V3 (pituitary) receptors. Its critical-care role is V1-mediated vasoconstriction; the cognitive discussion involves central V1a effects on social behavior, mostly from human intranasal studies.
FAQ
Common questions
Is vasopressin a wellness, hydration, or cognition peptide?
No. The cited sources center on regulated vasopressin injection for adults with vasodilatory shock in critical-care settings. They do not answer wellness, hydration, cognition, sleep, social, or anti-aging claims.
Why is cardiac and ischemia risk emphasized?
Vasopressin is a vasoconstrictor. Labeling warns that it can worsen cardiac function and that overdose can reflect vasoconstriction in peripheral, mesenteric, and coronary vascular beds.
Do the label sources validate non-critical-care vasopressin use?
No. The approval and label evidence here is about inpatient critical-care use. It does not establish safety, product quality, or suitability for wellness, hydration, cognition, or other non-critical-care uses.
Details
Technical details
Sources
References
- 1.
DailyMed. VASOPRESSIN injection, solution prescribing information 2025.
Accessed 2026-06-09.
Current structured label source for vasopressin injection indication, V1/V2 mechanism, cardiac-function warning, reversible diabetes insipidus, pregnancy, pediatric, and overdose boundaries.
- 2.
FDA. Vasopressin Injection NDA 212593 approval letter 2020.
Accessed 2026-06-09.
FDA approval letter for vasopressin injection to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
- 3.
FDA. Vasopressin Injection NDA 212593 summary review 2020.
Accessed 2026-06-09.
FDA summary review source for approval context, vasodilatory shock indication, 505(b)(2) pathway, and reliance on listed-product safety and effectiveness context.
- 4.
PubMed. Vasopressin versus norepinephrine infusion in patients with septic shock 2008.
doi:10.1056/NEJMoa067373 PMID:18305265 Accessed 2026-06-09.
Large randomized septic-shock trial used for human critical-care evidence context, not general-use instructions.
- 5.
PubMed. Vasopressin in Vasodilatory Shock 2019.
PMID:30784607 Accessed 2026-06-09.
Clinical review source for vasodilatory-shock physiology, randomized-trial context, and safety framing around critical-care vasopressin use.
- 6.
FDA Vasostrict label. FDA prescribing information for Vasostrict, revised 2023.
Approved vasopressor use, warnings, adverse reactions, and pharmacology.
- 7.
Russell 2008 septic shock. Russell et al. 2008 vasopressin versus norepinephrine in septic shock.
Major ICU comparator trial.
- 8.
Gordon 2016 VANISH. Gordon et al. 2016 early vasopressin versus norepinephrine in septic shock.
Major ICU comparator trial.
- 9.
Parker 2019 autism pilot. Parker et al. 2019 randomized placebo-controlled pilot of intranasal vasopressin in children with autism.
Direct human autism efficacy signal.
- 10.
Autism phase 2 registry. ClinicalTrials.gov protocol NCT03204786.
Larger autism study design and safety-monitoring context.
- 11.
Guastella 2010 face encoding. Guastella et al. 2010 happy and angry face encoding study.
Acute social-memory signal.
- 12.
Guastella 2011 cues. Guastella et al. 2011 sexual cue recognition study.
Acute cue-salience signal.
- 13.
Zink 2010 mPFC-amygdala. Zink et al. 2010 medial prefrontal and amygdala circuitry study.
Neural-circuit mechanism evidence.
- 14.
Zink 2011 TPJ. Zink et al. 2011 temporoparietal junction social-recognition activity study.
Neural-circuit mechanism evidence.
- 15.
Rilling 2012 cooperation. Rilling et al. 2012 cooperative behavior and brain activity in men.
Social-interaction evidence.
- 16.
Rilling 2014 sex differences. Rilling et al. 2014 sex differences in neural and behavioral response.
Sex-specific social-processing evidence.
- 17.
Wu 2018 cue ERP. Wu et al. 2018 adult and infant cue-processing ERP study.
Context-dependent social processing.
- 18.
Wu 2019 communication ERP. Wu et al. 2019 gender-specific social communication ERP study.
Sex- and cue-dependent effects.
- 19.
Zhuang 2021 attention. Zhuang et al. 2021 social attention study.
Top-down and bottom-up social-attention effects.
- 20.
Perras 1997 memory. Perras et al. 1997 verbal memory after three months of intranasal vasopressin.
Older memory data.
- 21.
Perras 1999 sleep. Perras et al. 1999 age-related sleep-disturbance study.
Older sleep data.
- 22.
Perras 2003 HPA sleep. Perras et al. 2003 sleep and pituitary-adrenal inhibition study.
Older sleep and safety context.
- 23.
Pietrowsky 1996 delivery. Pietrowsky et al. 1996 intranasal versus IV brain-potential change study.
Delivery-mechanism evidence.
- 24.
Ludwig 2013 intranasal challenge. Ludwig et al. 2013 rat intranasal challenge study.
Delivery skepticism.
- 25.
Yao 2022 delivery review. Yao et al. 2022 review of intranasal oxytocin and vasopressin.
Balanced intranasal-delivery discussion.
- 26.
Parker 2018 CSF biomarker. Parker et al. 2018 CSF vasopressin as a sociality marker.
Biomarker rationale.
- 27.
Oztan 2026 CSF biomarker. Oztan et al. 2026 CSF vasopressin biomarker and hypothalamic gene-expression study.
Brain-relevant autism biomarker argument.
- 28.
Balovaptan phase 2. Balovaptan phase 2 signal in adult men with autism spectrum disorder.
Vasopressin-pathway comparator.
- 29.
Balovaptan negative RCTs. Later negative adult and pediatric balovaptan randomized trials.
Cautionary vasopressin-pathway comparator.
- 30.
FDA compounding risks. FDA compounding risk materials.
Regulatory and safety context for compounded products.
- 31.
FDA 503B bulks list. FDA 503B bulks list page.
Current list status for vasopressin.
- 32.
Federal Register 2019. Federal Register 2019 vasopressin compounding determination.
Why vasopressin was not included on the 503B bulks list.
- 33.
FDA Q7A COA guidance. FDA Q7A guidance on supplier certificates of analysis.
COA limitations.
- 34.
De Spiegeleer 2008. De Spiegeleer et al. 2008 impurity profiling of synthetic peptides.
Gray-market peptide quality risk.
- 35.
Currier 2007 impurities. Currier et al. 2007 peptide impurities in commercial synthetic peptides.
Synthetic-peptide quality-risk support.
- 36.
Ashraf 2024 semaglutide quality. Ashraf et al. 2024 multifactor gray-market semaglutide quality and safety analysis.
Endotoxin and contamination-risk context in peptide markets.
- 37.
RUO vasopressin listing. Research-reagent vasopressin sales page marked laboratory use only.
Gray-market signal.
- 38.
Additional RUO listings. Additional research-use vasopressin product pages.
Gray-market signal.
- 39.
Forums and nootropic pages. Legacy nootropic, anti-aging, and forum discussion pages.
Search intent and anecdote only.